GLYCOGEN SYNTHASE KINASE-3〉 REGULATES EX-VIVO EXPANSION AND ENGRAFTMENT OF UMBILICAL CORD BLOOD HEMATOPOIETIC STEM CELLS THROUGH ACTIVATION OF WNT SIGNALLING
Wnt signalling plays an important role in the regulation of hematopoiesis. Previous murine experiments have demonstrated activation of Wnt by different methodologies including use of recombinant Wnt proteins, bone marrow stoma cells producing Wnt proteins or by over-expression of constitutively active ␤-catenin gene, the main downstream effector of Wnt. Together these studies provide evidence that Wnt signalling positively regulates self-renewal of murine hematopoietic stem cells (HSCs). An alternate approach to achieve Wnt activation is by inhibition of glycogen synthase kinase-3␤ (GSK-3␤), which prevents degradation of ␤-catenin. We have explored the role of GSK-3␤ inhibition and Wnt activation as a means to expand ex-vivo human umbilical cord blood (UCB) cells. We have shown that GSK-3␤ inhibition suppresses ex-vivo proliferation of UCB cells induced by cytokines but improves the repopulating capacity of UCB. Using a synthetic GSK-3␤ inhibitor (6-bromoindirubin 3'-oxime; BIO) co-cultured with UCB CD34ϩ cells, we demonstrate that GSK-3␤ inhibition suppresses ex-vivo expansion of committed HPCs while increasing the pool of the most primitive progenitor/stem cells. UCB C34ϩ cells cultured in BIO results in the accumulation of ␤-catenin and its re-location from the cytoplasm to the cell nucleus. In addition up-regulation of c-myc and HoxB4 genes both known ␤-catenin targets involved in the regulation of stem cell renewal was observed. GSK-3␤ inhibition also down-regulates cyclin D1 and up-regulates p21 Waf1 which may also account for reduced cell cycling and maintenance of HSCs in BIO-treated UCB cells. Additionally, GSK-3␤ inhibition increased CXCR4 expression and adherence of UCB cells to stroma and reduced apoptosis in UCB cells co-cultured with bone marrow stroma. Both delayed cell cycling and reduced apoptosis may account for the increased output of primitive progenitor/stem cells in BIO-treated UCB observed in-vivo in the "humanised" NOD/SCID mouse model. Using this model we have demonstrated both expansion and preservation of function with increased numbers of engrafting BIO treated human CD34ϩ UCB (120-fold expansion) compared to control cells (45-fold expansion). In addition, increased output of myeloid, lymphoid and megakaryocitic progenitor cells was observed in NOD/SCID mice that received BIO-treated UCB cells. The increased expansion of human NOD/SCID repopulating cells suggests improved maintenance of stem cell function during exvivo expansion of UCB in the presence of BIO. Significantly higher frequencies of SCID Repopulating Cells (SRC) were observed in BIO-treated UCB cells by limiting dilution analysis. Increased SRC numbers may result from the reduced apoptosis in BIOtreated UCB cell cultures. The increased expression of CXCR4 resulting in the improved interaction of UCB cells with bone marrow stroma, may also contribute to the increased SRC numbers in BIO-treated UCB cells. In summary, using a humanized NOD/ SCID mouse model we have shown that activation of the Wnt pathway through GSK-3␤ inhibition improves the repopulating ability of human UCB hematopoietic progenitor/stem cells.
DELTA1: A NOTCH UP ON CORD BLOOD TRANSPLANTATION? Colleen Delaney, MD, MSC Fred Hutchinson Cancer Research Center, Seattle, Washington
Current evidence indicates a role for Notch signaling in regulating cell-fate decisions of hematopoietic precursors. Earlier work performed in our lab demonstrated enhanced self-renewal of repopulating cells due to retrovirus-mediated expression of a constitutively active form of Notch1. Subsequent studies demonstrated that activation of endogenous Notch receptors by exogenously presented Notch ligand was able to expand precursor cell numbers from human and murine non-mutant stem cells, including those with short-term and, in the case of human cells, possibly long-term repopulating ability. Based on these findings, we have developed a novel, Notch-ligand based, clinically relevant cGMP expansion system for CD34 ϩ UCB progenitors, using an engineered form of the Notch ligand, Delta1, consisting of the extracellular domain of Delta1 fused to the Fc domain of human IgG1 (Delta1 ext-IgG ). In this effort, we have demonstrated a relationship between Delta1 ext-IgG density and induced expression of the Notch target gene, Hes1, and that ligand dose plays a critical role in determination of HSC fate (Delaney et al, Blood, 106(8): 2693 -9, Oct 2005 . In preclinical studies utilizing this system, culture of UCB progenitors with Delta1 ext-IgG significantly enhanced the magnitude and kinetics of marrow repopulation of immunodeficient mice. Moreover, limiting dilution assays demonstrated a 15.8 fold increase in repopulating cell (SRC) frequency in Delta1-cultured cells compared to non-cultured cells at 3 weeks (pϭ0.0001) post infusion of cells and a 6.3 fold increase in SRC frequency at 9 weeks (pϭ0.0001), indicating a significant increase in repopulating ability after culture with Delta1 ext-IgG . Finally, important to the clinical objective of overcoming the delayed engraftment associated with UCBT, the kinetics of rapid early human engraftment were evaluated at 10 days in mice transplanted with Delta1-cultured cells as compared to non-cultured cells. There was no measurable contribution to engraftment 10 days post transplant in mice receiving non-cultured cord blood cells, whereas the mice which received Delta1-cultured cells resulted in all mice engrafting at a level of Ͼ0.5% human engraftment. This data further suggests that culture with Delta1 ext-IgG dramatically enhances the early engraftment potential of cord
